Roche Diagnostics received FDA approval for its cobas HIV-1/HIV-2 Qualitative Test on the fully automated cobas 6800/8800 Systems in the United States, putting the HIV diagnostics market on the fast track

 

HIV diagnostics are not as simple to acquire as they may appear to be, and it's important that you get the correct tests for your particular condition. One shouldn't be embarrassed or feel ashamed about getting tested for the disease; after all, there are a lot of people who are living with HIV or AIDS and are leading happy lives. The reason you're being tested is simply so you can get the proper medical help you need, which can help you combat this dangerous disease.

Growing prevalence of HIV/AIDS is expected to drive growth of the global HIV diagnostics market. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2019, 38 million people were living with HIV across the globe, of which 36.2 million were adults and 1.8 million were children aged 15 years and below. According to the same source, around 1.7 million people across the globe acquired HIV in 2019. Such increasing prevalence has led to high demand for advanced HIV diagnostics devices and testing kits across the globe. Hence, such factors are expected to drive growth of the global HIV diagnostics market. Increasing proactive initiatives to create awareness regarding HIV/AIDS is expected to propel the global HIV diagnostics market growth in the near future. For instance, in December 2020, Manforce Condom, a product of Mankind Pharma, launched a new campaign titled “#StandTogether” to raise awareness regarding HIV.

Lack of mandates for the nucleic acid test (NAT) and high costs associated with it in emerging economies is expected to restrain growth of the global HIB diagnostics market. Among regions, North America is expected to witness significant growth in the global HIV diagnostics market. This is owing to the presence of a technologically advanced healthcare network and higher expenditure in R&D. Furthermore, Asia Pacific is expected to register a robust growth rate, owing to the presence of high unmet demand in China and India.

Major companies involved in the global HIV diagnostics market are Alere Inc., Qiagen, Abbott Healthcare, Siemens Healthcare, Abbvie Inc., Roche Diagnostics, Bristol-Myers Squibb, Mylan Inc., Janssen Therapeutics, Zyomyx Inc., Gilead Sciences, PointCare Technologies Inc., Merck & Co. Inc., Apogee Flow Systems, VIIV Healthcare, Sysmex, BD Biosciences, Partec, and Beckman Coulter.

For instance, in September 2020, Roche Diagnostics received the U.S. Food and Drug Administration (FDA) approval for its cobas HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas 6800/8800 Systems in the U.S.